Cover Image
Market Research Report

HIV Disease Coverage Forecast and Market Analysis to 2024

Published by Datamonitor Healthcare Product code 633173
Published Content info 717 Pages
Delivery time: 1-2 business days
Price
Back to Top
HIV Disease Coverage Forecast and Market Analysis to 2024
Published: January 25, 2019 Content info: 717 Pages
Description

Overview

The human immunodeficiency virus, or HIV, is a retrovirus that infects the cells of the immune system such as T lymphocytes, specifically cluster of differentiation-4+ T cells, dendritic cells, and macrophages. Infection leads to a progressive weakening of the immune system and ultimately results in acquired immunodeficiency syndrome (AIDS).

Market Snapshot

  • B/F/TAF will drive significant revenue growth due to its attractive combination of an INSTI and a preferred backbone.
  • TAF-based regimens are rapidly cannibalizing the share of TDF-based products due to superior renal and bone safety.
  • HIV prevalence is increasing in the analyzed markets as people are living longer on antiretroviral therapy.
  • Rapid uptake of TAF-based regimens in the US will protect Gilead's revenues following TDF patent expiry.
  • B/F/TAF's potency and clean tolerability profile will outcompete its rivals, restricting their uptake at launch.
Table of Contents
Product Code: DMKC 5240

TABLE OF CONTENTS

FORECAST: HIV (Published on 22 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ATRIPLA
  • PRODUCT PROFILE (LATE STAGE): B/F/TAF
  • PRODUCT PROFILE: COMPLERA
  • PRODUCT PROFILE (LATE STAGE): DOR/3TC/TDF
  • PRODUCT PROFILE: DESCOVY
  • PRODUCT PROFILE: GENVOYA
  • PRODUCT PROFILE: ISENTRESS
  • PRODUCT PROFILE: JULUCA
  • PRODUCT PROFILE: ODEFSEY
  • PRODUCT PROFILE: PREZISTA FRANCHISE
  • PRODUCT PROFILE: REYATAZ FRANCHISE
  • PRODUCT PROFILE: STRIBILD
  • PRODUCT PROFILE: SYMTUZA
  • PRODUCT PROFILE: TIVICAY
  • PRODUCT PROFILE (LATE STAGE): TIVICAY/EPIVIR
  • PRODUCT PROFILE: TRIUMEQ
  • PRODUCT PROFILE: TRUVADA
  • PRODUCT PROFILE (LATE STAGE): CABOTEGRAVIR/RILPIVIRINE
  • PRODUCT PROFILE (LATE STAGE): FOSTEMSAVIR

TREATMENT: HIV (Published on 13 April 2018)

  • OVERVIEW
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • TREATMENT GUIDELINES
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN HIV
  • IMPACT OF GENERICS

EPIDEMIOLOGY: HIV (Published on 25 January 2019)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: HIV (Published on 22 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ATRIPLA
  • PRODUCT PROFILE: COMPLERA
  • PRODUCT PROFILE: DESCOVY
  • PRODUCT PROFILE: GENVOYA
  • PRODUCT PROFILE: ISENTRESS
  • PRODUCT PROFILE: JULUCA
  • PRODUCT PROFILE: ODEFSEY
  • PRODUCT PROFILE: PREZISTA FRANCHISE
  • PRODUCT PROFILE: REYATAZ FRANCHISE
  • PRODUCT PROFILE: STRIBILD
  • PRODUCT PROFILE: SYMTUZA
  • PRODUCT PROFILE: TIVICAY
  • PRODUCT PROFILE: TRIUMEQ
  • PRODUCT PROFILE: TRUVADA

PIPELINE: HIV (Published on 22 December 2017)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES
  • PRODUCT PROFILE (LATE STAGE): B/F/TAF
  • PRODUCT PROFILE (LATE STAGE): DOR/3TC/TDF
  • PRODUCT PROFILE (LATE STAGE): TIVICAY/EPIVIR
  • PRODUCT PROFILE (LATE STAGE): CABOTEGRAVIR/RILPIVIRINE
  • PRODUCT PROFILE (LATE STAGE): FOSTEMSAVIR

LIST OF FIGURES

  • Figure 1: HIV - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for HIV
  • Figure 3: HIV total market value across the US and five major EU markets, by country, 2017-26
  • Figure 4: HIV total market value across the US and five major EU markets, by class, 2017-26
  • Figure 5: HIV sales in the US, 2017-26
  • Figure 6: HIV sales in the five major EU markets, by country, 2017-26
  • Figure 7: Sales of B/F/TAF compared to INSTI-based STRs and injections, by product, 2017-26
  • Figure 8: Sales of ViiV Healthcare's oral two-drug regimens compared to B/F/TAF and Symtuza, by product, 2017-26
  • Figure 9: HIV sales across the US and five major EU markets, by company, 2017-26
  • Figure 10: Datamonitor Healthcare's HIV forecast methodology
  • Figure 11: Price sources and calculations, by country
  • Figure 12: Atripla for HIV - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of Atripla for HIV
  • Figure 14: Datamonitor Healthcare's drug assessment summary of Atripla for HIV
  • Figure 15: Atripla sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 16: B/F/TAF for HIV - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary of B/F/TAF for HIV
  • Figure 18: Datamonitor Healthcare's drug assessment summary of B/F/TAF for HIV
  • Figure 19: B/F/TAF sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 20: Complera for HIV - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Complera for HIV
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Complera for HIV
  • Figure 23: Complera sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 24: DOR/3TC/TDF for HIV - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of DOR/3TC/TDF for HIV
  • Figure 26: Datamonitor Healthcare's drug assessment summary of DOR/3TC/TDF for HIV
  • Figure 27: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 28: Descovy for HIV - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Descovy for HIV
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Descovy for HIV
  • Figure 31: Descovy sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 32: Genvoya for HIV - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of Genvoya for HIV
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Genvoya for HIV
  • Figure 35: Genvoya sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 36: Isentress for HIV - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Isentress for HIV
  • Figure 38: Datamonitor Healthcare's drug assessment summary of Isentress for HIV
  • Figure 39: Isentress sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 40: Juluca for HIV - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Juluca for HIV
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Juluca for HIV
  • Figure 43: Juluca sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 44: Odefsey for HIV - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Odefsey for HIV
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Odefsey for HIV
  • Figure 47: Odefsey sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 48: Prezista franchise for HIV - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Prezista franchise for HIV
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Prezista franchise for HIV
  • Figure 51: Prezista sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 52: Prezcobix sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 53: Reyataz franchise for HIV - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Reyataz franchise for HIV
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Reyataz franchise for HIV
  • Figure 56: Reyataz sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 57: Evotaz sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 58: Stribild for HIV - SWOT analysis
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Stribild for HIV
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Stribild for HIV
  • Figure 61: Stribild sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 62: Symtuza for HIV - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Symtuza for HIV
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Symtuza for HIV
  • Figure 65: Symtuza sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 66: Tivicay for HIV - SWOT analysis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Tivicay for HIV
  • Figure 68: Datamonitor Healthcare's drug assessment summary of Tivicay for HIV
  • Figure 69: Tivicay sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 70: Tivicay/Epivir for HIV - SWOT analysis
  • Figure 71: Datamonitor Healthcare's drug assessment summary of Tivicay/Epivir for HIV
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Tivicay/Epivir for HIV
  • Figure 73: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 74: Triumeq for HIV - SWOT analysis
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Triumeq for HIV
  • Figure 76: Datamonitor Healthcare's drug assessment summary of Triumeq for HIV
  • Figure 77: Triumeq sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 78: Truvada for HIV - SWOT analysis
  • Figure 79: Datamonitor Healthcare's drug assessment summary of Truvada for HIV
  • Figure 80: Datamonitor Healthcare's drug assessment summary of Truvada for HIV
  • Figure 81: Truvada sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 82: Cabotegravir/rilpivirine for HIV - SWOT analysis
  • Figure 83: Datamonitor Healthcare's drug assessment summary of cabotegravir/rilpivirine for HIV
  • Figure 84: Datamonitor Healthcare's drug assessment summary of cabotegravir/rilpivirine for HIV
  • Figure 85: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 86: Fostemsavir for HIV - SWOT analysis
  • Figure 87: Datamonitor Healthcare's drug assessment summary of fostemsavir for HIV
  • Figure 88: Datamonitor Healthcare's drug assessment summary of fostemsavir for HIV
  • Figure 89: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 90: Percentage of HIV prevalent population who are diagnosed and undiagnosed in the US and five major EU markets, by country
  • Figure 91: Percentage of the HIV-diagnosed population under physician care in the US and five major EU markets, by country
  • Figure 92: Breakdown of pharmacologically treated HIV patients in the US and five major EU markets, by line of therapy and country
  • Figure 93: Percentage of respondents in the US and five major EU markets who agree with initiating treatment in all patients, by country
  • Figure 94: Treatment status of HIV patients under physician care in the US and five major EU markets, by country
  • Figure 95: Top five brands used for the treatment of first-line HIV patients, by country
  • Figure 96: Top five regimens used for the treatment of first-line HIV patients, by country
  • Figure 97: Top five regimens used for the treatment of second-line HIV patients, by country
  • Figure 98: Top five brands used for the treatment of second-line HIV patients, by country
  • Figure 99: Top five regimens used for the treatment of third-line HIV patients, by country
  • Figure 100: Top five brands used for the treatment of third-line HIV patients, by country
  • Figure 101: Top five regimens used for the treatment of fourth-line and beyond HIV patients, by country
  • Figure 102: Top five brands used for the treatment of fourth-line and beyond HIV patients, by country
  • Figure 103: Relative importance of unmet needs in HIV treatment in the US and five major EU markets, by country
  • Figure 104: Physician views on potential adherence impact of breaking up FDCs in HIV in the US and five major EU markets, by country
  • Figure 105: Extent of physician comfort with breaking up FDCs to prescribe separate generic components in HIV in the US and five major EU markets, by country
  • Figure 106: Physician views on whether cost savings justify the breaking up of FDCs in HIV in the US and five major EU markets, by country
  • Figure 107: Atripla for HIV - SWOT analysis
  • Figure 108: Datamonitor Healthcare's drug assessment summary of Atripla for HIV
  • Figure 109: Datamonitor Healthcare's drug assessment summary of Atripla for HIV
  • Figure 110: Atripla sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 111: Complera for HIV - SWOT analysis
  • Figure 112: Datamonitor Healthcare's drug assessment summary of Complera for HIV
  • Figure 113: Datamonitor Healthcare's drug assessment summary of Complera for HIV
  • Figure 114: Complera sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 115: Descovy for HIV - SWOT analysis
  • Figure 116: Datamonitor Healthcare's drug assessment summary of Descovy for HIV
  • Figure 117: Datamonitor Healthcare's drug assessment summary of Descovy for HIV
  • Figure 118: Descovy sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 119: Genvoya for HIV - SWOT analysis
  • Figure 120: Datamonitor Healthcare's drug assessment summary of Genvoya for HIV
  • Figure 121: Datamonitor Healthcare's drug assessment summary of Genvoya for HIV
  • Figure 122: Genvoya sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 123: Isentress for HIV - SWOT analysis
  • Figure 124: Datamonitor Healthcare's drug assessment summary of Isentress for HIV
  • Figure 125: Datamonitor Healthcare's drug assessment summary of Isentress for HIV
  • Figure 126: Isentress sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 127: Juluca for HIV - SWOT analysis
  • Figure 128: Datamonitor Healthcare's drug assessment summary of Juluca for HIV
  • Figure 129: Datamonitor Healthcare's drug assessment summary of Juluca for HIV
  • Figure 130: Juluca sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 131: Odefsey for HIV - SWOT analysis
  • Figure 132: Datamonitor Healthcare's drug assessment summary of Odefsey for HIV
  • Figure 133: Datamonitor Healthcare's drug assessment summary of Odefsey for HIV
  • Figure 134: Odefsey sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 135: Prezista franchise for HIV - SWOT analysis
  • Figure 136: Datamonitor Healthcare's drug assessment summary of Prezista franchise for HIV
  • Figure 137: Datamonitor Healthcare's drug assessment summary of Prezista franchise for HIV
  • Figure 138: Prezista sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 139: Prezcobix sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 140: Reyataz franchise for HIV - SWOT analysis
  • Figure 141: Datamonitor Healthcare's drug assessment summary of Reyataz franchise for HIV
  • Figure 142: Datamonitor Healthcare's drug assessment summary of Reyataz franchise for HIV
  • Figure 143: Reyataz sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 144: Evotaz sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 145: Stribild for HIV - SWOT analysis
  • Figure 146: Datamonitor Healthcare's drug assessment summary of Stribild for HIV
  • Figure 147: Datamonitor Healthcare's drug assessment summary of Stribild for HIV
  • Figure 148: Stribild sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 149: Symtuza for HIV - SWOT analysis
  • Figure 150: Datamonitor Healthcare's drug assessment summary of Symtuza for HIV
  • Figure 151: Datamonitor Healthcare's drug assessment summary of Symtuza for HIV
  • Figure 152: Symtuza sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 153: Tivicay for HIV - SWOT analysis
  • Figure 154: Datamonitor Healthcare's drug assessment summary of Tivicay for HIV
  • Figure 155: Datamonitor Healthcare's drug assessment summary of Tivicay for HIV
  • Figure 156: Tivicay sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 157: Triumeq for HIV - SWOT analysis
  • Figure 158: Datamonitor Healthcare's drug assessment summary of Triumeq for HIV
  • Figure 159: Datamonitor Healthcare's drug assessment summary of Triumeq for HIV
  • Figure 160: Triumeq sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 161: Truvada for HIV - SWOT analysis
  • Figure 162: Datamonitor Healthcare's drug assessment summary of Truvada for HIV
  • Figure 163: Datamonitor Healthcare's drug assessment summary of Truvada for HIV
  • Figure 164: Truvada sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 165: B/F/TAF for HIV - SWOT analysis
  • Figure 166: Datamonitor Healthcare's drug assessment summary of B/F/TAF for HIV
  • Figure 167: Datamonitor Healthcare's drug assessment summary of B/F/TAF for HIV
  • Figure 168: B/F/TAF sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 169: DOR/3TC/TDF for HIV - SWOT analysis
  • Figure 170: Datamonitor Healthcare's drug assessment summary of DOR/3TC/TDF for HIV
  • Figure 171: Datamonitor Healthcare's drug assessment summary of DOR/3TC/TDF for HIV
  • Figure 172: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 173: Tivicay/Epivir for HIV - SWOT analysis
  • Figure 174: Datamonitor Healthcare's drug assessment summary of Tivicay/Epivir for HIV
  • Figure 175: Datamonitor Healthcare's drug assessment summary of Tivicay/Epivir for HIV
  • Figure 176: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 177: Cabotegravir/rilpivirine for HIV - SWOT analysis
  • Figure 178: Datamonitor Healthcare's drug assessment summary of cabotegravir/rilpivirine for HIV
  • Figure 179: Datamonitor Healthcare's drug assessment summary of cabotegravir/rilpivirine for HIV
  • Figure 180: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country, 2017-26
  • Figure 181: Fostemsavir for HIV - SWOT analysis
  • Figure 182: Datamonitor Healthcare's drug assessment summary of fostemsavir for HIV
  • Figure 183: Datamonitor Healthcare's drug assessment summary of fostemsavir for HIV
  • Figure 184: Fostemsavir sales for HIV across the US and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: HIV sales across the US and five major EU markets, by company ($m), 2017-26
  • Table 2: Molecules and brands included in Datamonitor Healthcare's patient-based HIV forecast
  • Table 3: Exchange rates used for calculating prices
  • Table 4: Infectious disease specialists surveyed for the HIV primary research study, 2017
  • Table 5: Atripla drug profile
  • Table 6: Atripla pivotal data in HIV
  • Table 7: Atripla sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 8: B/F/TAF drug profile
  • Table 9: B/F/TAF Phase III data in HIV
  • Table 10: B/F/TAF Phase III trials in HIV
  • Table 11: B/F/TAF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 12: Complera drug profile
  • Table 13: Complera pivotal data in HIV
  • Table 14: Complera other late-phase trial data in HIV
  • Table 15: Complera sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 16: DOR/3TC/TDF drug profile
  • Table 17: DOR/3TC/TDF Phase III data in HIV
  • Table 18: DOR/3TC/TDF Phase III trials in HIV
  • Table 19: Doravirine Phase III trials in HIV
  • Table 20: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 21: Descovy drug profile
  • Table 22: Descovy pivotal data in HIV
  • Table 23: Descovy other late-phase trials in HIV
  • Table 24: Descovy sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 25: Genvoya drug profile
  • Table 26: Genvoya pivotal data in HIV
  • Table 27: Genvoya other late-phase data in HIV
  • Table 28: Genvoya ongoing late-phase trials in HIV
  • Table 29: Genvoya sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 30: Isentress drug profile
  • Table 31: Isentress pivotal data in HIV
  • Table 32: Isentress sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 33: Juluca drug profile
  • Table 34: Juluca Phase III data in HIV
  • Table 35: Juluca sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 36: Odefsey drug profile
  • Table 37: Odefsey pivotal data in HIV
  • Table 38: Odefsey other late-phase data in HIV
  • Table 39: Odefsey sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 40: Prezista drug profile
  • Table 41: Prezcobix drug profile
  • Table 42: Prezista pivotal data in HIV
  • Table 43: Prezista pivotal data in HIV
  • Table 44: Prezista sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 45: Prezcobix sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 46: Reyataz drug profile
  • Table 47: Evotaz drug profile
  • Table 48: Reyataz pivotal data in HIV
  • Table 49: Reyataz other late-phase data in HIV
  • Table 50: Reyataz other late-phase data in HIV
  • Table 51: Reyataz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 52: Evotaz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 53: Stribild drug profile
  • Table 54: Stribild pivotal data in HIV
  • Table 55: Stribild other late-phase data in HIV
  • Table 56: Stribild sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 57: Symtuza drug profile
  • Table 58: Symtuza pivotal data in HIV
  • Table 59: Symtuza sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 60: Tivicay drug profile
  • Table 61: Tivicay pivotal data in HIV
  • Table 62: Tivicay pivotal data in HIV
  • Table 63: Tivicay ongoing late-phase clinical trials in HIV
  • Table 64: Tivicay sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 65: Tivicay/Epivir drug profile
  • Table 66: Tivicay/Epivir Phase III trials in HIV
  • Table 67: Tivicay/Epivir Phase II data in HIV
  • Table 68: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 69: Triumeq drug profile
  • Table 70: Triumeq pivotal data in HIV
  • Table 71: Triumeq other late-phase data in HIV
  • Table 72: Triumeq sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 73: Truvada drug profile
  • Table 74: Truvada pivotal data in HIV
  • Table 75: Truvada pivotal data in HIV
  • Table 76: Truvada sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 77: Cabotegravir/rilpivirine drug profile
  • Table 78: Cabotegravir/rilpivirine Phase III trials in HIV
  • Table 79: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 80: Fostemsavir drug profile
  • Table 81: Fostemsavir Phase III trial in HIV
  • Table 82: Fostemsavir Phase II data in HIV
  • Table 83: Fostemsavir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 84: Infectious disease specialists surveyed for the HIV primary research study, 2017
  • Table 85: Therapies discussed in the HIV key opinion leader primary research study, 2017
  • Table 86: HIV total infections, new infections, and AIDS-attributable deaths, by region, 2016
  • Table 87: New HIV diagnoses in the US and five major EU markets, by transmission route, 2016
  • Table 88: Per-act HIV transmission risk, by transmission route
  • Table 89: CDC classification system for HIV-infected adults and adolescents
  • Table 90: Symptomatic conditions included in CDC HIV classification system clinical categories
  • Table 91: WHO clinical staging of HIV/AIDS for adults and adolescents
  • Table 92: Treatments available for HIV across the US and five major EU markets
  • Table 93: Summary of "recommended" treatment options in HHS and EACS treatment guidelines
  • Table 94: HIV prevalence, infections, and AIDS-attributable deaths in 2017, by region
  • Table 95: Sources used for the epidemiological analysis of HIV in the US, Japan, and five major EU markets, by country
  • Table 96: Data sources used to describe the diagnosed prevalent HIV population, by country
  • Table 97: Data sources used to segment diagnosed incident HIV cases by AIDS at diagnosis, by country
  • Table 98: Data sources used to segment diagnosed incident HIV cases by transmission category, by country
  • Table 99: Diagnosed incident cases of HIV in the US, Japan, and five major EU markets, by country, 2018-28
  • Table 100: Incident cases of HIV diagnosed at AIDS stage, in adults, in the US, Japan, and five major EU markets, by country, 2018
  • Table 101: Number and proportion of incident HIV cases, by transmission route, and country, 2018
  • Table 102: Total prevalent cases of HIV in the US, Japan, and five major EU markets, by country, 2018-28
  • Table 103: Diagnosed and undiagnosed prevalent HIV cases, by country, 2018
  • Table 104: Co-morbid bone and renal impairments in adult diagnosed prevalent HIV cases, by country, 2018
  • Table 105: Key marketed drugs for HIV
  • Table 106: Atripla drug profile
  • Table 107: Atripla pivotal data in HIV
  • Table 108: Atripla sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 109: Complera drug profile
  • Table 110: Complera pivotal data in HIV
  • Table 111: Complera other late-phase trial data in HIV
  • Table 112: Complera sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 113: Descovy drug profile
  • Table 114: Descovy pivotal data in HIV
  • Table 115: Descovy other late-phase trials in HIV
  • Table 116: Descovy sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 117: Genvoya drug profile
  • Table 118: Genvoya pivotal data in HIV
  • Table 119: Genvoya other late-phase data in HIV
  • Table 120: Genvoya ongoing late-phase trials in HIV
  • Table 121: Genvoya sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 122: Isentress drug profile
  • Table 123: Isentress pivotal data in HIV
  • Table 124: Isentress sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 125: Juluca drug profile
  • Table 126: Juluca Phase III data in HIV
  • Table 127: Juluca sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 128: Odefsey drug profile
  • Table 129: Odefsey pivotal data in HIV
  • Table 130: Odefsey other late-phase data in HIV
  • Table 131: Odefsey sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 132: Prezista drug profile
  • Table 133: Prezcobix drug profile
  • Table 134: Prezista pivotal data in HIV
  • Table 135: Prezista pivotal data in HIV
  • Table 136: Prezista sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 137: Prezcobix sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 138: Reyataz drug profile
  • Table 139: Evotaz drug profile
  • Table 140: Reyataz pivotal data in HIV
  • Table 141: Reyataz other late-phase data in HIV
  • Table 142: Reyataz other late-phase data in HIV
  • Table 143: Reyataz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 144: Evotaz sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 145: Stribild drug profile
  • Table 146: Stribild pivotal data in HIV
  • Table 147: Stribild other late-phase data in HIV
  • Table 148: Stribild sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 149: Symtuza drug profile
  • Table 150: Symtuza pivotal data in HIV
  • Table 151: Symtuza sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 152: Tivicay drug profile
  • Table 153: Tivicay pivotal data in HIV
  • Table 154: Tivicay pivotal data in HIV
  • Table 155: Tivicay ongoing late-phase clinical trials in HIV
  • Table 156: Tivicay sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 157: Triumeq drug profile
  • Table 158: Triumeq pivotal data in HIV
  • Table 159: Triumeq other late-phase data in HIV
  • Table 160: Triumeq sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 161: Truvada drug profile
  • Table 162: Truvada pivotal data in HIV
  • Table 163: Truvada pivotal data in HIV
  • Table 164: Truvada sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 165: Key Phase III pipeline products in development for HIV
  • Table 166: B/F/TAF drug profile
  • Table 167: B/F/TAF Phase III data in HIV
  • Table 168: B/F/TAF Phase III trials in HIV
  • Table 169: B/F/TAF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 170: DOR/3TC/TDF drug profile
  • Table 171: DOR/3TC/TDF Phase III data in HIV
  • Table 172: DOR/3TC/TDF Phase III trials in HIV
  • Table 173: Doravirine Phase III trials in HIV
  • Table 174: DOR/3TC/TDF sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 175: Tivicay/Epivir drug profile
  • Table 176: Tivicay/Epivir Phase III trials in HIV
  • Table 177: Tivicay/Epivir Phase II data in HIV
  • Table 178: Tivicay/Epivir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 179: Cabotegravir/rilpivirine drug profile
  • Table 180: Cabotegravir/rilpivirine Phase III trials in HIV
  • Table 181: Cabotegravir/rilpivirine sales for HIV across the US and five major EU markets, by country ($m), 2017-26
  • Table 182: Fostemsavir drug profile
  • Table 183: Fostemsavir Phase III trial in HIV
  • Table 184: Fostemsavir Phase II data in HIV
  • Table 185: Fostemsavir sales for HIV across the US and five major EU markets, by country ($m), 2017-26
Back to Top